RecruitingPhase 2NCT06645691

Hyperpolarized MR Imaging with Carbon-13 Pyruvate in the Human Body


Sponsor

National Heart Centre Singapore

Enrollment

200 participants

Start Date

Oct 17, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

Positron emission tomography with 18F fluorodeoxyglucose (FDG) is the conventional imaging technique to provide information regarding tissue glucose uptake and has been highly clinically successful. However, it cannot assess downstream metabolism, which may be useful in the diagnosis and assessment of treatment response in a variety of diseases. Patients will also be exposed to ionizing radiation, the amount of exposure can vary depending on the dose of tracer administered, frequency of scans and duration of each scan. Carbon-13 (13C) magnetic resonance imaging (MRI) is particularly attractive for metabolic imaging because carbon serves as the backbone of nearly all organic molecules in the body. With this technique, the polarization increases to approximately 30%-40%, an increase of over 10,000 to 100,000-fold, thereby dramatically increasing the MRI signal . Whilst the role of 13C imaging has been demonstrated in many sites around the world, we aim to demonstrate the feasibility and application of 13C hyperpolarized imaging in healthy Singapore residents and patients with cardiovascular and/or cardiometabolic diseases.


Eligibility

Min Age: 21 YearsMax Age: 99 Years

Plain Language Summary

Simplified for easier understanding

This study is testing a new MRI imaging technique using hyperpolarized carbon-13 pyruvate — a specially prepared, non-radioactive substance — to measure how the body's cells use energy. This could help doctors better understand and diagnose heart disease, diabetes, and other metabolic conditions. **You may be eligible if...** - You are 21 years or older - You are either a healthy volunteer with no major medical conditions, OR - You have a diagnosed heart or metabolic condition such as ischemic heart disease, cardiomyopathy, stable heart failure, diabetes, or high blood pressure - You are willing and able to undergo MRI scanning **You may NOT be eligible if...** - You have a pacemaker, metal implants, or other contraindications to MRI - You have unstable medical conditions such as uncontrolled heart failure, unstable blood pressure, or active arrhythmias - You are pregnant or breastfeeding - You have a known allergy to pyruvate Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGHyperpolarized 13C-pyruvate

Hyperpolarized 13C-pyruvate is injected intravenously at a dose of 0.43 mL/kg body weight, and at a rate of 5 mL/second followed by a 20 mL saline flush at 5 mL/second when the patient is already in the MRI scanner


Locations(1)

National Heart Centre Singapore

Singapore, Singapore

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06645691


Related Trials